Β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release

Retrovirology

Volumn 8, Issue , 2011, Pages

  Tervo, Hanna Mari ^a   Homann, Stefanie ^a,b   Ambiel, Ina ^a   Fritz, Joëlle V ^a   Fackler, Oliver T ^a   Keppler, Oliver T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN 1; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN 2; CARRIER PROTEINS AND BINDING PROTEINS; CD4 ANTIGEN; CELL PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VPU PROTEIN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL LEVEL; CELL SURFACE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; VIRION; VIRUS RELEASE; CELL LINE; CELL MEMBRANE; DOWN REGULATION; GENETICS; HELA CELL; HUMAN; METABOLISM; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIGENS, CD; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELL LINE; CELL MEMBRANE; DOWN-REGULATION; GPI-LINKED PROTEINS; HELA CELLS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRION; VIRUS RELEASE;

EID: 79751526122     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-9     Document Type: Article

References (52)

1. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009, 83(4):1837-1844. 10.1128/JVI.02211-08, 2643743, 19036818.
2. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451(7177):425-430. 10.1038/nature06553, 18200009.
3. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2009, 83(5):2382-2385. 10.1128/JVI.01607-08, 2643706, 19091864.
4. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009, 106(8):2886-2891. 10.1073/pnas.0811014106, 2650360, 19179289.
5. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV, Fruh K. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 2009, 83(19):9672-9681. 10.1128/JVI.00597-09, 2748026, 19605472.
6. Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P, Towers GJ, Neil SJ. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog 2010, 6(4):e1000843. 10.1371/journal.ppat.1000843, 2855335, 20419159.
7. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K, Kuhn JH, Sandwick S, Ruthel G, Kota K, Boltz D, Warren T, Kranzusch PJ, Whelan SP, Bavari S. Infectious Lassa virus but not filoviruses is restricted by BST-2/tetherin. J Virol 2010, 84(20):10569-10580. 10.1128/JVI.00103-10, 20686043.
8. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 2010, 84(24):12646-12657. 10.1128/JVI.01328-10, 20943977.
9. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3(4):245-252. 10.1016/j.chom.2008.03.001, 2474773, 18342597.
10. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139(3):499-511. 10.1016/j.cell.2009.08.039, 2844890, 19879838.
11. Bartee E, McCormack A, Fruh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2006, 2(10):e107. 10.1371/journal.ppat.0020107, 1626102, 17238276.
12. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, Krijnse-Locker J, Banting G, Kräusslich HG, Fackler OT, Keppler OT. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5(3):285-297. 10.1016/j.chom.2009.01.009, 19286137.
13. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 2009, 5(5):e1000443. 10.1371/journal.ppat.1000443, 2678251, 19461879.
14. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009, 5(9):e1000574. 10.1371/journal.ppat.1000574, 2729927, 19730691.
15. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 2009, 5(5):e1000450. 10.1371/journal.ppat.1000450, 2679223, 19478868.
16. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 2009, 284(50):35060-35072. 10.1074/jbc.M109.058305, 2787367, 19837671.
17. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol 2010, 84(8):4089-4094. 10.1128/JVI.01549-09, 2849503, 20147395.
18. Habermann A, Krijnse-Locker J, Oberwinkler H, Eckhardt M, Homann S, Andrew A, Strebel K, Krausslich HG. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J Virol 2010, 84(9):4646-4658. 10.1128/JVI.02421-09, 2863769, 20147389.
19. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol 1992, 66(1):226-234. 238279, 1727486.
20. Bour S, Perrin C, Akari H, Strebel K. The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem 2001, 276(19):15920-15928. 10.1074/jbc.M010533200, 11278695.
21. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998, 1(4):565-574. 10.1016/S1097-2765(00)80056-8, 9660940.
22. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, Margottin-Goguet F, Jackson PK, Yamasaki L, Pagano M. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 2003, 4(6):799-812. 10.1016/S1534-5807(03)00154-0, 12791266.
23. Nakayama K, Hatakeyama S, Maruyama S, Kikuchi A, Onoe K, Good RA, Nakayama KI. Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci USA 2003, 100(15):8752-8757. 10.1073/pnas.1133216100, 166385, 12843402.
24. Butticaz C, Michielin O, Wyniger J, Telenti A, Rothenberger S. Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J Virol 2007, 81(3):1502-1505. 10.1128/JVI.01711-06, 1797504, 17121803.
25. Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A, Specht A, Sauter D, Dobner T, Kirchhoff F. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 2010, 7(1):1. 10.1186/1742-4690-7-1, 2823648, 20078884.
26. Schubert U, Bour S, Ferrer-Montiel AV, Montal M, Maldarell F, Strebel K. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 1996, 70(2):809-819. 189883, 8551619.
27. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009, 83(16):7931-7947. 10.1128/JVI.00242-09, 2715753, 19515779.
28. Zhang J, Liang C. BST-2 diminishes HIV-1 infectivity. J Virol 2010, 84(23):12336-12343. 10.1128/JVI.01228-10, 20861258.
29. Belaidouni N, Marchal C, Benarous R, Besnard-Guerin C. Involvement of the betaTrCP in the ubiquitination and stability of the HIV-1 Vpu protein. Biochem Biophys Res Commun 2007, 357(3):688-693. 10.1016/j.bbrc.2007.03.195, 17445772.
30. Hattori K, Hatakeyama S, Shirane M, Matsumoto M, Nakayama K. Molecular dissection of the interactions among IkappaBalpha, FWD1, and Skp1 required for ubiquitin-mediated proteolysis of IkappaBalpha. J Biol Chem 1999, 274(42):29641-29647. 10.1074/jbc.274.42.29641, 10514433.
31. Li Y, Gazdoiu S, Pan ZQ, Fuchs SY. Stability of homologue of Slimb F-box protein is regulated by availability of its substrate. J Biol Chem 2004, 279(12):11074-11080. 10.1074/jbc.M312301200, 14707120.
32. Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z. HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene 1999, 18(12):2039-2046. 10.1038/sj.onc.1202760, 10321728.
33. Schubert U, Henklein P, Boldyreff B, Wingender E, Strebel K, Porstmann T. The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif. J Mol Biol 1994, 236(1):16-25. 10.1006/jmbi.1994.1114, 8107101.
34. Schubert U, Schneider T, Henklein P, Hoffmann K, Berthold E, Hauser H, Pauli G, Porstmann T. Human-immunodeficiency-virus-type-1-encoded Vpu protein is phosphorylated by casein kinase II. Eur J Biochem 1992, 204(2):875-883. 10.1111/j.1432-1033.1992.tb16707.x, 1541298.
35. Chen MY, Maldarelli F, Karczewski MK, Willey RL, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J Virol 1993, 67(7):3877-3884. 237753, 8510209.
36. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009, 5(2):e1000300. 10.1371/journal.ppat.1000300, 2633611, 19214216.
37. Callahan MA, Handley MA, Lee YH, Talbot KJ, Harper JW, Panganiban AT. Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. J Virol 1998, 72(6):5189-5197. 110095, 9573291.
38. Dutta S, Tan YJ. Structural and functional characterization of human SGT and its interaction with Vpu of the human immunodeficiency virus type 1. Biochemistry 2008, 47(38):10123-10131. 10.1021/bi800758a, 18759457.
39. Hussain A, Wesley C, Khalid M, Chaudhry A, Jameel S. Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J Virol 2008, 82(2):893-902. 10.1128/JVI.01373-07, 2224584, 17959659.
40. Hsu K, Seharaseyon J, Dong P, Bour S, Marban E. Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol Cell 2004, 14(2):259-267. 10.1016/S1097-2765(04)00183-2, 15099524.
41. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009, 5(5):e1000429. 10.1371/journal.ppat.1000429, 2673686, 19436700.
42. Le Tortorec A, Neil SJ. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 2009, 83(22):11966-11978. 10.1128/JVI.01515-09, 2772693, 19740980.
43. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6(1):54-67. 10.1016/j.chom.2009.05.008, 2852097, 19501037.
44. Keppler OT, Yonemoto W, Welte FJ, Patton KS, Iacovides D, Atchison RE, Ngo T, Hirschberg DL, Speck RF, Goldsmith MA. Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J Virol 2001, 75(17):8063-8073. 10.1128/JVI.75.17.8063-8073.2001, 115050, 11483751.
45. Pfeiffer T, Pisch T, Devitt G, Holtkotte D, Bosch V. Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells. FEBS Lett 2006, 580(15):3775-3778. 10.1016/j.febslet.2006.05.070, 16777098.
46. Wildum S, Schindler M, Munch J, Kirchhoff F. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 2006, 80(16):8047-8059. 10.1128/JVI.00252-06, 1563805, 16873261.
47. Nguyen KL, llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004, 319(2):163-175. 10.1016/j.virol.2003.11.021, 15015498.
48. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, Nakamichi I, Kikuchi A, Nakayama K, Nakayama K. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. Embo J 1999, 18(9):2401-2410. 10.1093/emboj/18.9.2401, 1171323, 10228155.
49. Keppler OT, Allespach I, Schuller L, Fenard D, Greene WC, Fackler OT. Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol 2005, 79(3):1655-1665. 10.1128/JVI.79.3.1655-1665.2005, 544094, 15650191.
50. Geuenich S, Goffinet C, Venzke S, Nolkemper S, Baumann I, Plinkert P, Reichling J, Keppler OT. Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology 2008, 5:27. 10.1186/1742-4690-5-27, 2288616, 18355409.
51. Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, Inazawa J, Oritani K, Itoh M, Ochi T, Ishihara K, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995, 26(3):527-534. 10.1016/0888-7543(95)80171-H, 7607676.
52. Michel N, Allespach I, Venzke S, Fackler OT, Keppler OT. The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol 2005, 15(8):714-723. 10.1016/j.cub.2005.02.058, 15854903.